(1.03%) 5 180.74 points
(0.46%) 38 852 points
(1.19%) 16 349 points
(0.51%) $78.88
(0.23%) $2.20
(0.12%) $2 334.10
(0.22%) $27.68
(0.19%) $966.70
(0.03%) $0.929
(0.04%) $10.83
(0.03%) $0.796
(-0.01%) $91.34
4.17% $ 0.125
Live Chart Being Loaded With Signals
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide...
Stats | |
---|---|
Dzisiejszy wolumen | 76 190.00 |
Średni wolumen | 382 721 |
Kapitalizacja rynkowa | 51.51M |
EPS | $0 ( 2024-02-25 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.25 |
ATR14 | $0.00100 (0.80%) |
Wolumen Korelacja
Starpharma Holdings Ltd Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Starpharma Holdings Ltd Korelacja - Waluta/Towar
Starpharma Holdings Ltd Finanse
Annual | 2023 |
Przychody: | $2.94M |
Zysk brutto: | $1.22M (41.60 %) |
EPS: | $-0.0400 |
FY | 2023 |
Przychody: | $2.94M |
Zysk brutto: | $1.22M (41.60 %) |
EPS: | $-0.0400 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $0 (0.00 %) |
EPS: | $0 |
FY | 2022 |
Przychody: | $4.68M |
Zysk brutto: | $1.91M (40.71 %) |
EPS: | $-0.0400 |
Financial Reports:
No articles found.
Starpharma Holdings Ltd
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej